Abstract
•
Four B cell–depleted non-Hodgkin lymphoma (NHL) patients with SARS-CoV-2 pneumonia after rituximab therapy were initially treated with a 5-day remdesivir course and steroids. After transient virologic and clinical response, they all experienced early relapse and subsequent prolonged disease course, with rapid and significant response to convalescent hyperimmune plasma in association with an extended course of remdesivir. The clinical observations here reported suggest that the immunological effects of Rituximab treatment in NHL patients should be taken into account for the proper choice and interpretation of SARS-CoV-2 laboratory tests and to guide the appropriate therapeutical approach.
Keywords: B cell depletion convalescent hyperimmune plasma remdesivir; Rituximab; SARS-CoV-2; non-Hodgkin lymphoma.
【저자키워드】 SARS-CoV-2, rituximab, B cell depletion convalescent hyperimmune plasma remdesivir, non-Hodgkin lymphoma., 【초록키워드】 Treatment, therapy, Pneumonia, Remdesivir, Steroids, B cell, Hyperimmune plasma, Patient, Interpretation, convalescent, association, Non-Hodgkin Lymphoma, Laboratory test, clinical response, prolonged disease, approach, Course, reported, subsequent, treated, clinical observation, immunological effect, NHL, patients with SARS-CoV-2, 【제목키워드】 response, Extended,